Why the study?
Valve-in-valve transcatheter aortic valve implantation is increasingly used to treat surgical bioprosthetic valve degeneration, but differences between balloon-expandable and self-expandable valves needed investigation.
Does valve-in-valve transcatheter aortic valve implantation with a balloon-expandable valve versus a self-expandable valve improve clinical outcomes and hemodynamic performance in patients with degenerated surgical bioprostheses?
Does valve-in-valve transcatheter aortic valve implantation with a balloon-expandable valve versus a self-expandable valve improve clinical outcomes and hemodynamic performance in patients with degenerated surgical bioprostheses?
Answers are grounded in this paper and cite their sources.
In patients undergoing ViV-TAVI for degenerated surgical bioprostheses, early hemodynamic advantages of self-expandable valves over balloon-expandable valves do not translate into long-term mortality benefits.
BACKGROUND: Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is increasingly used for the treatment of surgical bioprosthetic valve degeneration (sBVD). METHODS: We investigated clinical outcomes and hemodynamic valve performance in all consecutive patients undergoing ViV-TAVI for sBVD in a single centre and assessed differences in patients who received a balloon-expandable (BEV) versus self-expandable valve (SEV) at 1, 6 and 12 months (m), and annually thereafter. RESULTS: < 0.001, respectively). No significant differences in hemodynamic valve performance between BEV and SEV were observed during further follow-up. CONCLUSION: ViV-TAVI is a safe and effective treatment for patients presenting sBVD. Improved hemodynamic valve performance with SEV over BEV observed during early follow-up did not translate into long-term lower mortality rates.
No takes yet. Share an insight, caveat, or question.
Noé et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: